Michio brings a breadth of entrepreneurial, investing, and executive experience to the TDA where he is thrilled to continue to support great teams and great science. Prior to joining the TDA, Michio was the Chief Science Partner for Ataraxia VC, where he led seed stage lifescience investments in the U.S. and Europe. He is the co-founder and former CEO of Blue Therapeutics, a Boston-based biotech company developing novel CNS-acting compounds. Michio has an extensive academic research background, having published high impact work in the fields of immunology, neuroscience, and aging. He completed his PhD under an NRSA fellowship at Harvard (Clifford Woolf) before performing post-doctoral studies as an HHMI fellow at the Harvard Stem Cell Institute (Amy Wagers).